株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

プラダー・ウィリー症候群(PWS):パイプライン製品の分析

Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 321896
出版日 ページ情報 英文 100 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.33円で換算しております。
Back to Top
プラダー・ウィリー症候群(PWS):パイプライン製品の分析 Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2019
出版日: 2019年11月18日 ページ情報: 英文 100 Pages
概要

プラダー・ウィリー症候群(PWS)は、多くの身体機能障害、精神機能障害、行動障害が出生時に見られる、まれな遺伝性疾患です。症状は、筋肉の緊張低下、性ホルモンの低レベル、持続性の飢餓感などがあります。

当レポートでは、プラダー・ウィリー症候群(PWS)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向などについて、体系的な情報を提供しています。

目次

イントロダクション

プラダー・ウィリー症候群(PWS)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Chong Kun Dang Pharmaceutical Corp.
  • Essentialis, Inc.
  • Ferring International Center S.A.
  • LG Life Sciences, Ltd.
  • P2D Bioscience
  • Pfizer Inc.
  • Rhythm Pharmaceuticals

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • beloranib
  • betahistine hydrochloride
  • diazoxide choline CR
  • FE-992097
  • NOX-B11
  • setmelanotide
  • somatropin SR

パイプライン製品の最新動向

製品開発のマイルストーン

  • 注目のニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Prader-Willi Syndrome (PWS), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Prader-Willi Syndrome (PWS) - Pipeline by Auris Medical Holding Ltd, H2 2019
  • Prader-Willi Syndrome (PWS) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019
  • Prader-Willi Syndrome (PWS) - Pipeline by ConSynance Therapeutics Inc, H2 2019
  • Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center SA, H2 2019
  • Prader-Willi Syndrome (PWS) - Pipeline by GLWL Research Inc, H2 2019
  • Prader-Willi Syndrome (PWS) - Pipeline by Helsinn Group, H2 2019
  • Prader-Willi Syndrome (PWS) - Pipeline by Insys Therapeutics Inc, H2 2019
  • Prader-Willi Syndrome (PWS) - Pipeline by LG Chem Ltd, H2 2019
  • Prader-Willi Syndrome (PWS) - Pipeline by Millendo Therapeutics Inc, H2 2019
  • Prader-Willi Syndrome (PWS) - Pipeline by Neuracle Science Co Ltd, H2 2019
  • Prader-Willi Syndrome (PWS) - Pipeline by OptiNose US Inc, H2 2019
  • Prader-Willi Syndrome (PWS) - Pipeline by Rhythm Pharmaceuticals Inc, H2 2019
  • Prader-Willi Syndrome (PWS) - Pipeline by Saniona AB, H2 2019
  • Prader-Willi Syndrome (PWS) - Pipeline by Soleno Therapeutics Inc, H2 2019
  • Prader-Willi Syndrome (PWS) - Dormant Projects, H2 2019
  • Prader-Willi Syndrome (PWS) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Prader-Willi Syndrome (PWS), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
目次
Product Code: GMDHC11423IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2019, provides an overview of the Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline landscape.

Prader-Willi Syndrome (PWS) is a rare genetic disorder present at birth that results in a number of physical, mental and behavioral problems. PWS is due to lack of several genes on one of an individual's two chromosome 15's. In the majority of cases, there is a deletion. In remaining cases, the entire chromosome from the father is missing and there are instead two chromosome 15's from the mother (uniparental disomy). Symptoms include poor muscle tone, low levels of sex hormones and a constant feeling of hunger.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 3, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Prader-Willi Syndrome (PWS) - Overview
  • Prader-Willi Syndrome (PWS) - Therapeutics Development
  • Prader-Willi Syndrome (PWS) - Therapeutics Assessment
  • Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development
  • Prader-Willi Syndrome (PWS) - Drug Profiles
  • Prader-Willi Syndrome (PWS) - Dormant Projects
  • Prader-Willi Syndrome (PWS) - Discontinued Products
  • Prader-Willi Syndrome (PWS) - Product Development Milestones
  • Appendix
Back to Top